Ki-67 and overall survival in patients with glioblastoma: A systematic prognostic review and meta-analysis.

Ida Kaalhus Nordahl, Claes Johnstad, Ole Solheim, Sverre Helge Torp

Abstract readReview

In one paragraph

Review in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ida Kaalhus NordahlDepartment of Clinical and Molecular Medicine, Faculty of Health and Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.ORCID https://orcid.org/0009-0002-3946-8850

Claes JohnstadDepartment of Neuromedicine and Movement Science, Norwegian University of Science and Technology, Trondheim, Norway (C.J., O.S.).ORCID https://orcid.org/0009-0005-3928-5706

Ole SolheimDepartment of Neuromedicine and Movement Science, Norwegian University of Science and Technology, Trondheim, Norway (C.J., O.S.).ORCID https://orcid.org/0000-0002-5954-4817

Sverre Helge TorpDepartment of Clinical and Molecular Medicine, Faculty of Health and Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.ORCID https://orcid.org/0000-0001-8345-6852

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Ki-67 labeling index (LI) is widely used to quantify tumor proliferation in cancer. Although helpful in assessing proliferative activity across gliomas, its prognostic value in glioblastoma remains uncertain. Methods: We conducted a systematic prognostic review and meta-analysis of studies reporting associations between Ki-67 LI and overall survival in adult glioblastomas. Random-effects models (restricted maximum likelihood with Knapp-Hartung adjustments) were used to pool hazard ratios (HRs). Risk of bias was assessed with the QUIPS tool. Results: Fourteen retrospective cohort studies ( Conclusions: Higher Ki-67 LI is associated with an increased hazard of death in patients with glioblastoma, with effects persisting after multivariable adjustment and limited between-study heterogeneity. Standardized Ki-67 assessment and clinically validated cutoffs are needed to improve comparability and enable robust prognostic stratification.

Identifiers

PMID42211396

DOI10.1093/noajnl/vdag111

PMCPMC13213614

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.